# Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

> **NCT05548270** · PHASE3 · COMPLETED · sponsor: **Repurposed Therapeutics, Inc.** · enrollment: 503 (actual)

## Conditions studied

- Motion Sickness

## Interventions

- **DRUG:** DPI-386 Nasal Gel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05548270
- **Lead sponsor:** Repurposed Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-23
- **Primary completion:** 2022-11-29
- **Final completion:** 2022-11-29
- **Target enrollment:** 503 (ACTUAL)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05548270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05548270, "Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05548270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*